Review
Copyright ©The Author(s) 2015.
World J Gastroenterol. Jul 21, 2015; 21(27): 8271-8283
Published online Jul 21, 2015. doi: 10.3748/wjg.v21.i27.8271
Table 6 Lung or thoracic cancer studies n (%)
AuthorType of microsphereType of mets (patients)Response criteriaResponseMedian OS
(publish date and study type)(average dosage or activity)@ 1st assessment
Gaba et al[36]TherasphereSquamous cell lung cancer (2)PET CT2 (100) CRPatient 1: Alive 11 mo after SIRT
(8/2012, case report)(1.57-3 Gbq)@ 2-3 moPatient 2: Alive 2 mo after SIRT
Murthy et al[44]SIR-SpheresLung cancer (6)Unspecified1 (17) PR2.7 mo
(2/2008, RS)(no dosage info)2 carcinoids 3 adenocarcinomas@ unspecified1 (17) “minor response”
1 small cell carcinoma1 (17) SD
3 (50) PD
Reiner et al[46]SIR-SpheresNSCLC (1, data extracted from larger study)RECIST 1.11 (100) CR/PRNone
(1/2014, PC)(mean 1.5 Gbq)@ 4 mo